Vaccination Coverage Covid-19 and Self-Reported Adverse Post-Vaccination Events in Mbuji-Mayi, DR Congo
Year: 2025
Type: article
Abstract: Rebecca Musuamba Tshipata,1 Chadrack Kabeya Diyoka,2 Chijindu N Nwakama,3 Laetitia Ngongo Mwanvua,2 Faustin Ndjibu Mpoji,1 Claude Muamba Mubalamata,1 Stéphanie Mbelu Kanyinda,4 Davina Bilonda Kasekelayi,5 Barry Mutombo Munyangama,1 Justine Mbelu Kashala Snr,6 Criss Koba Mjumbe7 1Department of Public Health, Faculty of Medicine, Pharmacy and Public Health, University of Mbujimayi, Mbujimayi, Democratic Republic of Congo; 2School of Public Health, University of Lubumbashi, Lubumbashi, Democratic Republic of Congo; 3Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; 4Department of Gynecology, Faculty of Medicine, Pharmacy and Public Health, University of Mbujimayi, Mbujimayi, Democratic Republic of Congo; 5Department of Pediatry, Faculty of Medicine, Pharmacy and Public Health, University of Mbujimayi, Mbujimayi, Democratic Republic of Congo; 6Mbuji-Mayi Higher Technical Medical Institute, Mbujimayi, Democratic Republic of Congo; 7Department of Public Health, Faculty of Medicine, University of Lubumbashi, Lubumbashi, Democratic Republic of CongoCorrespondence: Criss Koba Mjumbe, Department of Public Health, Faculty of Medicine, University of Lubumbashi, Lubumbashi, Democratic Republic of Congo, Email [email protected] Chadrack Kabeya Diyoka, School of Public Health, University of Lubumbashi, Lubumbashi, Democratic Republic of Congo, Email [email protected]; [email protected]: This study examines covid-19 vaccine coverage among adults and describes self-reported post-vaccine adverse events and associated risk factors in Mbuji-Mayi.Patients and Methods: A cross-sectional study was conducted, with the study population including adults (18 years and older) who received at least one dose of vaccine in the Bonzola health zone in Mbuji-Mayi between 27 March 2023 and 27 June 2023. The Pearson chi-square test (χ 2) and multinomial logistic regression analyses were performed using IBM SPSS Statistics 29 and Epi Info 7.2.4.0 software.Results: A survey of 422 people showed that only 164 (38.86%) had been vaccinated, and 83.54% of these people had had bad reactions to the vaccine. Respondents were mainly men (50.4%) aged between 18 and 25 (52.44%). The most common vaccine was the Johnson & Johnson vaccine (43.8%), followed by the AstraZeneca vaccine (40.1%). The most frequent side effects after vaccination were moderate (fever and vomiting) and least frequent (cough and headache). The results of the multivariate analysis showed that age and sex (respectively 2,946 times (95% CI: 2,946– 197,279), 10,019 times (95% CI: 1,214– 82,660) and 55,489 times (95% CI: 5,742– 536,248) higher than that of men) were associated with the occurrence of self-reported post-vaccination side effects, as well as fever, headache and cough.Conclusion: In view of the sub-optimal rate of vaccination coverage, it is evident that the prevailing circumstances have not been immune to the occurrence of adverse events reported by stakeholders following vaccination against the new coronavirus (Covid-19). This underscores the necessity for rigorous safety monitoring. The dissemination of these findings, in conjunction with the results of vaccine clinical trials, has the potential to contribute to the reduction of mistrust, which is a persistent challenge in the context of vaccine hesitancy.Keywords: COVID-19 vaccine, vaccination coverages, adverse events following, self reports
Authors: Musuamba Tshipata R, Kabeya Diyoka C, Nwakama CN, Ngongo Mwanvua L, Ndjibu mpoji F, Muamba Mubalamata C, Mbelu Kanyinda S, Bilonda Kasekelayi D, Mutombo Munyangama B, Kashala Snr JM, Koba Mjumbe C
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7006661168
FWCI:
Cites:
Cited by:
Related to: